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Abstract
Background: Worldwide, about 1.3 million annual ischaemic strokes (IS) occur in adults aged <50 years. Of these
early-onset strokes, up to 50% can be regarded as cryptogenic or associated with conditions with poorly documented
causality like patent foramen ovale and coagulopathies.
Key hypotheses/aims: (1) Investigate transient triggers and clinical/sub-clinical chronic risk factors associated with
cryptogenic IS in the young; (2) use cardiac imaging methods exceeding state-of-the-art to reveal novel sources for
embolism; (3) search for covert thrombosis and haemostasis abnormalities; (4) discover new disease pathways using
next-generation sequencing and RNA gene expression studies; (5) determine patient prognosis by use of phenotypic and
genetic data; and (6) adapt systems medicine approach to investigate complex risk-factor interactions.
Design: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome
(SECRETO; NCT01934725) is a prospective multi-centre case–control study enrolling patients aged 18–49 years hospi-
talised due to first-ever imaging-proven IS of undetermined etiology. Patients are examined according to a standardised
protocol and followed up for 10 years. Patients are 1:1 age- and sex-matched to stroke-free controls. Key study elements
include centralised reading of echocardiography, electrocardiography, and neurovascular imaging, as well as blood sam-
ples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis. We aim to have 600 patient–
control pairs enrolled by the end of 2018.
Summary: SECRETO is aiming to establish novel mechanisms and prognosis of cryptogenic IS in the young and will
provide new directions for therapy development for these patients. First results are anticipated in 2019.
Keywords
Brain infarction, echocardiography, electrocardiography, embolism, middle aged, paradoxical embolism, patent foramen
ovale, prognosis, risk factors, stroke, thrombosis, young adult
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Introduction
Worldwide, about 1.3 million annual ischaemic strokes
(IS) occur prematurely in adults aged 18–49 years.1
Although the overall incidence of stroke in high-
income countries has been declining over the past few
decades, the incidence of early-onset IS has increased
since 1980s.2 The key diﬀerences that separate early-
onset IS at age <50 years from late-onset IS at a mean
age about 75 years are fewer pre-existing comorbidities,
a more diverse spectrum of known causes and a larger
proportion of cryptogenic causes in younger patients.3
Recent European hospital-based multi-centre studies
and the population-based Oxford Vascular Study sug-
gested a prevalence ranging from 33% to 50% for
cryptogenic IS in young adults.4–6 The proportion of
cryptogenic IS is larger in younger age groups – even
exceeding >50% among those aged <30 years.4,5
The reported prevalence of cryptogenic IS varies
with the completeness and timing of diagnostic evalu-
ation.7 Earlier studies may have lacked uniform criteria
for minimum diagnostic work-up or have not employed
standardised diagnostic schemes. They may not have
classiﬁed patients with low- or uncertain-risk sources
of cardioembolism in the cryptogenic group. Patent for-
amen ovale (PFO), a common feature in the popula-
tion, or other right-to-left shunts as potential sources
for paradoxical embolism exemplify the uncertainty of
determining the causal mechanisms of early-onset IS.8
It is plausible to assume that there must be several
concomitant factors contributing to IS risk in young
individuals manifesting as chronic or temporal condi-
tions, or just short-acting triggers immediately preced-
ing the stroke such as Valsalva-inducing activity. One
of the most examined aggregate of risk factors is the
combination of PFO and prothrombotic mutations.9
However, with or without PFO, the role of known pro-
thrombotic mutations and other investigated candidate
genes remains inconclusive,10–12 whereas data suggest
that genetic factors have a much stronger inﬂuence in
early-onset rather than late-onset IS.13
Due to the large proportion of cryptogenic events,
the evidence base to guide prevention and treatment of
early-onset IS remains poor. Nevertheless, several
studies show high rates of recurrent stroke and to
lesser extent other cardiovascular disease in the young
suggesting active underlying pathologies,14–16 also for
those with undetermined causes.17 To address the many
gaps in this ﬁeld and promote the understanding of risk
factors, mechanisms and prognosis of early-onset
cryptogenic IS, we generated the following study
hypotheses:
. transient risk factors or triggers, often overlooked in
clinical practice, substantially contribute to early-
onset cryptogenic IS;
. a range of unconventional chronic risk factors, such
as migraine with aura,18 less well-established
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abnormalities of thrombosis and haemostasis,19
some infections (e.g. periodontitis)20 and risk
factors for venous thrombosis21 play a role in
cryptogenic IS;
. most young patients with cryptogenic IS may fulﬁl
the recently proposed criteria for embolic stroke of
undetermined source (ESUS)22,23 therefore, apart
from the often-studied atrial pathologies, there
likely remain cardiac pathologies that go unnoticed
with the current cardiac imaging focus;24
. observing ﬁrm cardiac electrophysiological changes
with for example signal-averaged electrocardiog-
raphy (ECG) and magnetocardiography may reveal
hints for cardiac pathology pre-disposing to crypto-
genic IS;25
. a number of non-invasive parameters characterising
cardiovascular performance beyond current routine
(e.g. endothelial function, arterial stiﬀness, myocar-
dial perfusion) may additionally shed light on the
cardiovascular pathways of cryptogenic IS;
. next-generation sequencing (NGS), ribonucleic acid
(RNA) analysis to show gene expression, and family
studies utilising NGS may establish novel disease
pathways in this patient population;13
. there likely exist biologically complex interactions
between the transient and chronic overt or covert
risk factors, which may explain the elevated risk of
IS better than any of the factors alone; investigat-
ing such aggregate eﬀects requires sophisticated
computational methods adapted from systems
biology.
Here, we highlight the design and key protocol fea-
tures of the multi-centre international case–control
study: Searching for Explanations for Cryptogenic
Stroke in the Young: Revealing the Etiology,
Triggers, and Outcome (SECRETO).
Design
Overview and timelines
SECRETO (Clinicaltrials.gov.NCT01934725) is an
international prospective multi-centre case–control
study of young adults (age 18–49) presenting with an
imaging-proven ﬁrst-ever acute cryptogenic IS. Patients
are included after standardised diagnostic procedures –
including brain magnetic resonance imaging (MRI),
imaging of intracranial and extracranial vessels, echocar-
diography and screening for coagulopathies – and
stroke-free controls are included in a 1:1 fashion
matched to patient age, sex and ethnic group. Due to
the IS incidence of approximately 10/100,000 per year in
this age group,26 an international consortium will be
established to recruit a suﬃcient number of patients in
reasonable time. Currently, 20 dedicated centres are
enrolling participants (Figure 1). Recruitment of subjects
began in 2013 with a pilot phase to test feasibility of the
protocol and is anticipated to ﬁnish by the end of 2018
aiming to reach 600 patients and 600 control subjects.
We will aim at a 10-year follow-up for the patients.
Objectives
SECRETO involves six principal objectives: (1) inves-
tigate transient triggers and clinical/sub-clinical chronic
risk factors associated with early onset cryptogenic IS,
(2) develop a standardised echocardiography protocol
exceeding current state-of-the-art to compare cardiac
structural and functional ﬁndings in a case–control
study and use novel cardiac imaging methods and
track weak cardiac electromagnetic signals to establish
novel cardiac sources for embolism, (3) search for
covert thrombosis and haemostasis abnormalities asso-
ciated with cryptogenic IS, (4) ﬁnd out disease path-
ways using next-generation sequencing and RNA gene
expression studies, (5) ultimately adapt systems medi-
cine approach to investigate the complex interactions
between the identiﬁed transient risk factors and (6)
follow-up the patients to determine their prognosis
and factors associated with adverse outcomes.
Study population
All eﬀorts are made to consecutively recruit eligible
patients during the study period, irrespective of stroke
severity. Inclusion and exclusion criteria of patients and
controls appear in Table 1, along with minimum diag-
nostic investigations that should be performed as
promptly as possible after the patient is admitted,
within deﬁned time limits (Table 1). Standard operating
procedures guide investigators speciﬁcally in the clinical
work-up of established cardiac sources of embolism
and known rare causes of IS that should be ruled out.
Ancillary diagnostic investigations shall be performed
on individual basis, but for example screening of deep
vein thrombosis is highly recommended in patients with
a detected right-to-left shunt. Cryptogenic IS is deﬁned
according to ASCO classiﬁcation27 as absence of dis-
ease (grade 0), or, any of grade II (causality uncertain)
or grade III (unlikely a direct cause) pathology using
diagnostic testing of highest grade of evidence.
However, we apply a few adaptations to ASCO in
order to reﬂect the true uncertainty in clinical practice
in younger patients. For instance we include all cases
with PFO, intra-cardiac thrombus without identiﬁed
cardiac pathology, perforant artery occlusion without
evident co-existing hypertensive microangiopathy,
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known common coagulopathies, or so-called migrain-
ous infarction (online Supplemental Table 1).
Furthermore, for the goals of the study, inclusive,
rather than exclusive, inclusion criteria would be
more purposeful.
Stroke-free controls are preferably recruited from
population-based sources – for example using a mailing
list obtained from population register – to minimise
selection bias. Patients’ non-related proxies (e.g.
friends, partners, hospital staﬀ) can alternatively serve
as controls if population-based controls are unavail-
able. Controls are matched with case patients with
age (within 5 years), sex and ethnic group. As per
STROBE guidelines (Strengthening the Reporting of
Observational studies in Epidemiology; http://strobe-
statement.org), one control per one case should be
recruited at each study site.
Measures and clinical data at baseline in patients
Extensive clinical data are collected on study patients at
baseline, including chronic comorbidities, physiological
parameters, diagnostic procedures and their ﬁndings,
acute treatment and stroke-speciﬁc details including
neurological symptoms at presentation. A standard
12-lead ECG is obtained for future analysis on admis-
sion and after the acute phase. Transcranial Doppler
(TCD) with bubble test is performed, where available,
according to standardised protocol as a part of clinical
routine for the diagnosis of right-to-left shunt.
At the initial study visit, anthropometrics (height,
weight, waist and hip circumference), blood pressure
and heart rate are measured in a standardised
manner. Parts or adaptations of validated scales are
used to capture baseline information regarding social
Figure 1. Countries and centres currently enrolling participants for SECRETO.
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status, triggers (online Supplemental Table 2), sub-
stance abuse, preceding infections, stress, depression,
physical activity, diet, headaches, reproductive health
and family history (online Supplemental Table 3).
Results and timing of patients’ routine (i.e. outside
the study) thrombophilia testing are recorded.
Importantly, retesting of thrombophilia at 3-month
follow-up visit with >12 weeks from the initial testing
should follow if there are any initial abnormal results
(apart from genetic thrombophilia).
Standardising and central reading of key
diagnostic studies
The mandatory brain MRI sequences include axial dif-
fusion-weighted imaging (DWI), apparent diﬀusion
coeﬃcient maps, conventional T2-weighted or ﬂuid-
attenuated inversion recovery (FLAIR) and T2* or
susceptibility-weighted imaging sequences. Intra- and
extra-cranial brain supplying arteries including the
ascending aorta and aortic arch must be imaged either
with magnetic resonance angiography (MRA) or com-
puted tomography angiography (CTA). To rule out
intramural haematoma associated with cervical artery
dissection, axial fat-saturated T1-slices of the neck are
strongly recommended. Central reading of neuroimaging
studies occurs at the Imaging Core Laboratory at the
Medical University of Graz, Austria, and considers char-
acteristics of the acute ischaemic lesion(s), old infarcts,
microbleeds, white-matter hyperintensities, vascular
pathologies and anatomic variations.
A step-by-step performance protocol was developed
for transthoracic (TTE) and transesophageal echocar-
diography (TEE) to allow their accurate and blinded
central reading at the Echocardiography Core
Laboratory at the University of Bergen, Norway.
Table 1. Key inclusion criteria for patients and controls.
Patients
Inclusion criteria
(1) Age 18–49 at stroke onset
(2) Patient hospitalised due to first-ever imaging-proven cryptogenic ischaemic stroke after complete and timely minimum diagnostic
testing
 Acute ischaemic lesion should preferably be demonstrated by DWI MRI
 In rapidly resolving symptoms with negative DWI, initial CTA or MRA showing an arterial occlusion and/or perfusion-CT or
perfusion-MRI imaging of the ischaemic lesion is sufficient to evidence acute cerebral ischaemia
 Silent brain infarcts in the qualifying MRI or previous transient ischaemic attacks are allowed
Exclusion criteria
(1) Baseline minimum tests not obtained in the first week following stroke onset, including:
 Brain MRI
 Routine blood tests (blood count, C-reactive protein, fasting glucose, creatinine, activated partial thromboplastin time, total
cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, glycosylated haemoglobin
and haemoglobin electrophoresis in individuals of African origin)
(2) Other baseline minimum tests not obtained within the first 2 weeks following stroke onset, including:
 Imaging of cervicocephalic arteries by CTA, MRA or catheter angiography
 Transesophageal and transthoracic echocardiographya
 24-h Holter monitoring or continuous in-hospital electrocardiography monitoring with automated atrial fibrillation detection
for at least 24 h
 Screening for common thrombophilia,b including antiphospholipid antibodies and other coagulopathies; tests include antic-
ardiolipin antibodies, lupus anticoagulant, anti-b2-glycoprotein antibodies, factor V mutation (or aPC resistance ruled out),
factor II mutation, homocysteine, antithrombin III, protein C and protein S
(3) Patient otherwise not eligible for the study or adherent for follow-up or has concurrent disease affecting outcome
(4) Informed consent not obtained from the patient or a proxy
Controls
Inclusion criteria
(1) Age 18–49 years
(2) Absence of prior stroke
(3) Informed consent obtained from the participant
Note: DWI: diffusion-weighted imaging; MRI: magnetic resonance imaging; CTA: computed tomography angiography; MRA: magnetic resonance
angiography.
aTransthoracic echocardiography may remain the only cardiac imaging modality in cases with very severe stroke, receptive aphasia or swallowing
difficulties.
bAbnormal findings concerning coagulation shall be retested >12 weeks from initial testing or >4 weeks after cessation of anticoagulation at any later
time point.
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Particular emphasis will be placed on the measures of
left atrium, atrial septum, left atrial appendage, as well
as interatrial and intrapulmonary (delayed) shunts, but
also on structural and functional changes in the left
ventricle, left-sided heart valves and the aorta.
Furthermore, ECGs will be read at the Heart and
Lung Center, Helsinki University Hospital, Finland.
Clinical investigations in controls
Apart from stroke-speciﬁc items, controls undergo
similar structured interview and clinical examination
of patients at baseline. At pre-selected study sites,
depending on local resources and ethics regulations,
controls may also systematically undergo voluntary
echocardiography and/or TCD bubble test with identi-
cal protocols to patients.
Investigational blood samples
Blood is drawn twice from patients, at the time of
enrollment and at 3-month visit, and once from
controls. Samples include ethylenediaminetetraacetic
acid (EDTA) whole blood, EDTA plasma, sodium cit-
rate plasma and serum, aliquoted into cryovials.
Furthermore, sodium citrate tubes with PPACK (d-
phenylalanyl-l-prolyl-l-arginine chloromethylketone;
thrombin inhibitor) are collected for the analysis of
other biomarkers, including intrinsic coagulation
factors. The samples allow analysis of separate path-
ways that may be coexistent with and pre-dispose to
thrombosis, covering exome- and whole-genome
sequencing, gene expression analysis with RNA
(including miRNA), analysis of coagulation factors,
infection serology and biomarkers characterising for
example endothelial dysfunction and cardiovascular
stress. Blood samples are pre-processed according to a
standardised protocol and shipped to the Biobank Core
Lab at the Institute for Molecular Medicine Finland,
University of Helsinki.
Follow-up
Follow-up of patients is performed face-to-face at man-
datory 3-month follow-up visit and, thereafter, either
with annual telephone contacts or clinical visits for up
to 10 years. At the 3-month visit, a clinical examination
and an additional ECG should be taken. Patient pheno-
type is recorded by ASCO classiﬁcation27 using all
available diagnostic information. Functional outcome
is assessed with modiﬁed Rankin Scale and Barthel
Index at each follow-up contact. Cognition, mood, anx-
iety, quality of life, caregiver burden and professional
life are assessed with validated scales used in multi-
centre studies and suitable for telephone interview.
Outcome events
Death, new cardiovascular events, cardiovascular
procedures occurring after the index stroke and medi-
cation are registered at each follow-up contact.
Furthermore, investigators are instructed to quarterly
evaluate all available medical records to identify any
hospitalisations or follow-up brain or vascular imaging
results suggestive of occurrence of endpoint events.
Death certiﬁcates and autopsy reports are reviewed in
the case of death. Events are initially queried by the
local investigator and then subjected to centralised
adjudication by the Clinical Endpoints Committee
based on the source documents.
Investigator-reported events subjected to adjudica-
tion include transient ischaemic attack (TIA), ischaemic
and haemorrhagic stroke, retinal vascular event, acute
coronary syndrome, peripheral arterial thrombosis or
systemic embolism, deep venous thrombosis, pulmon-
ary embolism and new-onset atrial ﬁbrillation. The pri-
mary endpoint events of interest are non-fatal or fatal
ischaemic cerebrovascular event (i.e. IS or TIA).
Sub-studies
In a single-centre pilot study including 120 case–control
pairs, we aim to assess carotid intima media thickness
with ultrasound, endothelial function with EndoPAT
device, arterial stiﬀness with applanation tonometry
(SphygmoCor device) and from that derive sub-
endocardial viability ratio. Furthermore, we perform
24-h ambulatory blood pressure recording and study
subtle cardiac electrophysiological features using
signal-averaged ECG and magnetocardiography. Other
pilot investigations, such as cardiorespiratory sleep study
with a three-channel portable device (ApneaLink Plus)
to screen sleep-disordered breathing and cardiac MRI/
CT or 3D echocardiography may also be employed.
SECRETO Oral is a four-centre sub-study undertak-
ing structured questionnaire on dental health and oral
hygiene habits, clinical oral examination, digital pano-
ramic tomography and collecting investigational saliva
and plaque samples from gingival pockets in about 300
patients and controls. Samples will be used to study
oral microbiota and inﬂammatory biomarkers.
In the SECRETO Family Study, we screen for a
wide range of early-onset vascular disease manifest-
ations before age 60 among the families of all young
index patients. The aim is to enrol at least 50 genetically
informative families and perform exome- or whole-
genome sequencing on the samples.
Sample size considerations
The study involves multiple case–control and
case–crossover analyses and smaller pilot studies with
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diﬀering prevalence between the studied exposures.
Assuming an alpha error of 0.05 and power of 80%,
a 1:1 matched case–control study with dichotomous
outcome with hypothesised 25% exposure prevalence
in control subjects (corresponding to e.g. PFO popula-
tion prevalence) the sample of 600 pairs would produce
probability of exposure-discordant pairs of 41.2%, and,
depending on the number of matching factors in multi-
variable model (ranging from none to 8 in this scen-
ario), we would be able to detect a minimum odds ratio
(OR) ranging from 1.43 to 2.31. If the prevalence
of exposure of interest in controls be as low as 1%
(as could be for rare variants associated with a hyper-
coagulable state) then the smallest detectable OR would
be 3.30.
In a case–crossover study, each subject forms his or
her own stratum and is his or her own control.
Generally, less than half as many subjects may be
needed for a case–crossover study as for case–control
study. The most important determinant of sample size
is the rarity of the trigger and/or frequency of discord-
ance, whereas the power can be further raised by
increasing the number of control periods. A prior
study including 200 general IS patients was able to
identify three independent triggers.28 Our sample of
600 patients allows detection of triggers with a min-
imum detectable OR of 1.5 with power of >80% and
alpha of 0.5, assuming exposure prevalence of >20% in
one control period. With the same assumptions but
using four control periods instead of just one, the
power can be increased up to >90%.
For the 600 patients, with an attrition of 10% we
expect a maximum of 5400 patient follow-up years with
a 10-year follow-up period. A conservative annual rate
of about 1.5% for the primary endpoint17,29 would cor-
respond to approximately 80 events. With 600 patients,
10% drop out rate, a cumulative risk of primary end-
point of 15%, an alpha of 0.05, a power of 80%, preva-
lence of exposure varying from 10% to 50% and a
limited squared multiple-correlation coeﬃcient ranging
from 0 to 0.2, we are able to pick an eﬀect of hazard
ratios approximately between 2 and 3 (two sided) in
Cox proportional hazards models.
Statistical analysis plan
Statistical tests for related samples will be used for uni-
variate matched case–control analyses. Independent
associations will be assessed using conditional logistic
regression to calculate ORs adjusting for potential con-
founders. As an alternative, Poisson regression may be
used to calculate relative risks. Stratiﬁed analyses will
be performed for pre-speciﬁed sub-groups, i.e. for sexes
and PFO(þ) vs. PFO(), with further deﬁning PFOs as
either potentially incidental or culprit using a proposed
index.30 Analyses will consider possible heterogeneity
between study centres. Adjustment for confounding in
etiological research questions will be determined based
on prior knowledge and can be executed with multi-
variable regression, propensity score matching or
adjustment or inverse probability weighting. Missing
data will be, where appropriate and needed, be imputed
or accounted for through inverse probability weighting.
Case–crossover methodology will be employed in
stroke trigger analyses. We will record exposure to
triggers during speciﬁed time intervals and then per-
form within-individual comparisons of the trigger
activities at diﬀerent times. Each individual serves as
his/her own control and thus accounts for the inter-
individual diﬀerences in any confounding factors. ORs
and 95% conﬁdence intervals will be calculated for
each trigger.
For univariate time-to-event analyses, Kaplan–
Meier analysis and log-rank tests will be used to test
the diﬀerence between the dichotomous covariates.
Univariate Cox proportional hazards methods will
be ﬁrst used to examine hazard ratios. The models
will be then adjusted for potential confounders accord-
ing to the outcome of interest.
Current status of recruitment
As of October 2016, 123 patients and 76 controls have
been enrolled. Key numbers of this preliminary cohort
appear in an online Supplemental Table 4.
Discussion
Each year more than half a million young individuals
are struck by IS in which the cause remains elusive
despite extensive modern-day diagnostic work-up.
There is limited knowledge how to prevent these strokes
and the patients are left without targeted secondary
prevention. Young patients who have suﬀered a crypto-
genic IS may also have to live in uncertainty even for
decades. Bearing in mind the increasing incidence of IS
at younger ages, early-onset cryptogenic IS is one of the
most important ﬁelds of research in stroke medicine.
Potential physical, chemical and psychological trig-
gers are frequently reported by the patients in clinical
practice, all of which we aim to cover in the study
protocol. Our study explores, whether there is any asso-
ciation between pre-existing well-documented vascular
risk factors and early-onset cryptogenic IS. Based on
the high overall frequency of classical vascular risk fac-
tors in young IS patients,31 there are reasons to
hypothesise that such associations also appear for
young cryptogenic IS, but probably patterns and mech-
anisms diﬀer from those for typical late-onset causes.
Of the known but less well-documented chronic risk
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factors, migraine with aura is perhaps the most attract-
ive one since its prevalence in our pilot data set was
more than sixfold compared with controls (online
Supplemental Table 4) and because there is a number
of biologically plausible hypotheses linking migraine
with aura and IS.18
Our project will likely provide novel data on trig-
gers and thrombosis and haemostasis pathways lead-
ing to IS. A particular strength in this domain
include two time points for collecting samples,
during the sub-acute phase and at 3 months, which
allows exclusion of possible acute phase stroke-
related alterations in the thrombosis and haemostasis
and biomarker proﬁles. Moreover, we utilise PPACK-
inhibitor tubes to examine activities of intrinsic
coagulation factors, a promising but understudied
area of stroke precipitants.19
Early-onset stroke represents an extreme phenotype
carrying more potential to ﬁnd rare genetic variants.13
Meta-analysing our patients with existing young cohorts
for a genome-wide association study is an option, but
remains hampered by a relatively low number of cases.32
NGS techniques (exome and whole-genome sequencing)
have become more widely aﬀordable and oﬀer larger
potential to robustly identify rare, high penetrance vari-
ants. Furthermore, adding these techniques to a trad-
itional genetic family study is attractive, and, although
not accounting for large number of cases, even a single
informative family may reveal new rare variants unravel-
ling previously unknown biochemical pathways involved
in the pathogenesis of IS in the young.
The follow-up study will describe long-term risks of
recurrent IS and TIA, other vascular endpoints, as well
as other secondary, functional, neuropsychological and
social outcomes. Since there have not been solid criteria
for cryptogenic stroke before the introduction of
ESUS,22 the estimated risk of primary endpoint (recur-
rent IS or TIA) is merely based on indirect assumptions
and resulted in rather conservative number of expected
events. Yet, all clinically relevant vascular events will be
recorded during follow-up which allows much more
comprehensive characterisation of the vascular
prognosis.
Regular screening and adherence to study protocol is
essential for the success of patient recruitment and to
ensure that adequate and timely diagnostic work-up is
carried out. Such a policy may improve overall diag-
nostic accuracy and quality of cryptogenic IS even
during the study course.33 Factors possibly inﬂuencing
selection of controls, such as recruiting them from other
than population-based sources or unintended selection
of persons who are exceptionally excited about their
health, may not all be completely avoided, while
many of such factors can be taken into account in stat-
istical analyses.
Certain ethical aspects should be acknowledged.
TTE, TEE and TCD bubble test will be performed in
consenting control subjects at pre-selected sites.
TTE has no known side eﬀects and imposes virtually
no risks. Complication risk attributable to TEE was
0.2–0.5% in a study population that included patients
with a heart disease,34 a rate similar to that of gastros-
copy. TEE will not be performed if any contraindica-
tion is present that is disease of upper gastrointestinal
tract. TCD bubble test, if performed according to
current consensus guidelines did not convey marked
side-eﬀects even in the presence of structural cardiac
abnormalities.35 If any clinically relevant ﬁnding arise
in the investigations of controls with results readily
available, he/she will be directed to an appropriate
unit for further work-up.
In conclusion, the SECRETO study will likely dis-
cover novel disease pathways underlying early-onset
cryptogenic IS. New factors inﬂuencing prognosis
may be revealed. Our project will also reﬁne the clinical
work-up in cryptogenic IS – particularly with respect to
cardiac evaluation – and improve understanding of the
interaction between heart and brain in younger patients
with cryptogenic IS, as well as eventually aid in ﬁnding
new targets for treatment development. Finally, our
study paves the way for future randomised trials testing
diﬀerent treatment strategies in the secondary preven-
tion of early-onset IS.
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